Crebankitug Biosimilar Monoclonal Antibody (IL-7Rα) for Research

Cat No.: GMP-Bios-INN-1143

Anti-IL7R/CD127 therapeutic antibody (Pre-made Crebankitug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Crebankitug (development code ZB-168) is a monoclonal antibody targeting IL-7 receptor alpha (IL7R). It is developed by Pfizer and Zura Bio for atopic dermatitis, ulcerative colitis, multiple sclerosis among others. It is in Phase II clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1143-1mg 1mg 3090
GMP-Bios-INN-1143-10mg 10mg
GMP-Bios-INN-1143-100mg 100mg
GMP-Bios-INN-1143-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Crebankitug biosimilar, Whole mAb, Anti-IL7R/CD127 Antibody: Anti-IL-7Ra/CD127/IL7R/Interleukin-7 receptor subunit alpha therapeutic antibody
INN Name Crebankitug
Target IL7R/CD127
Format Whole mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Lambda
Highest_Clin_Trial (Jan '20) Phase-II
Est. Status Active
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2024
Year Recommended 2024
Companies Pfizer;Zura Bio
Conditions Approved na
Conditions Active Atopic dermatitis;Ulcerative colitis;Multiple sclerosis;Type 1 diabetes mellitus;Alopecia areata;Immunological disorders
Conditions Discontinued TBC
Production na
Development Tech na